Advertisements



FDA approves Alnylam"s Onpattro as hATTR treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

FDA Approves $450,000-a-Year Treatment for Rare Disease

Patients who have hereditary transthyretin-mediated amyloidosis, or hATTR, will take the drug for the rest of their lives. Alnylam Phar.....»»

Category: europeSource: fortuneAug 11th, 2018

Alnylam confirms FDA approves Onpattro to treat polyneuropathy caused by hATTR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam"s Onpattro approved by FDA to treat polyneuropathy caused by hATTR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

FDA approves marketing of L.A. company"s ADHD treatment device

The U.S. Food and Drug Administration announced it will allow the maker of the first medical device approved to treat attention deficit hyperactivity disorder (ADHD) in children to market the non-invasive treatment in the United States. The FDA .....»»

Category: topSource: bizjournalsApr 22nd, 2019

FDA approves marketing of ADHD treatment device

The U.S. Food and Drug Administration announced it will allow the maker of the first medical device approved to treat attention deficit hyperactivity disorder (ADHD) in children to market the non-invasive treatment in the United States. The FDA grant.....»»

Category: topSource: bizjournalsApr 22nd, 2019

Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic .....»»

Category: dealsSource: nytApr 15th, 2019

Alnylam"s Givosiran study met primary efficacy endpoint in AHP treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 12th, 2019

Amgen says FDA approves EVENITY for treatment of osteoporosis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 9th, 2019

FDA approves Amgen"s Evenity for treatment of osteoporosis in postmenopausal women

The U.S. Food and Drug Administration on Tuesday approved Amgen Inc's drug Evenity for the treatment of ost.....»»

Category: topSource: marketwatchApr 9th, 2019

FDA approves Dovato as complete regimen for treatment-naive HIV infected adults

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2019

Gilead announces Japan"s MHLW approves Biktarvy for HIV-1 treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 26th, 2019

FDA approves new treatment for postpartum depression

The FDA has approved biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the market and o.....»»

Category: topSource: bizjournalsMar 20th, 2019

FDA Approves First Drug Treatment for Postpartum Depression

But it requires an IV drip for 60 hours at a health care facility. The U.S. Food and Drug Administration (FDA) has approved a drug for the first time that aims at treating p.....»»

Category: europeSource: fortuneMar 20th, 2019

FDA approves first postpartum depression drug — it could help hundreds of thousands of new mothers

A new treatment for postpartum depression, called brexanolone, was approved by the Food and Drug Administration on Tuesday......»»

Category: topSource: marketwatchMar 20th, 2019

FDA approves Sage"s first-ever treatment for postpartum depression

The FDA has approved Cambridge biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the market.....»»

Category: topSource: bizjournalsMar 19th, 2019

FDA approves Sage Therapeutics" Zulresso in PPD treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2019

Alnylam & Medison Partner to Market RNAi Products in Israel

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates und.....»»

Category: worldSource: nytJan 22nd, 2019

Alnylam, Israel"s Medison partner to commercialize Onpattro, RNAi portfolio

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 21st, 2019

N.J. approves Legacy Treatment Services" affiliation with Woods Services

New Jersey officials have approved a deal that will allow Legacy Treatment Services to formerly affiliate with Woods Services in Bucks County. The affiliation deal is part of Langhorne-based Woods Services’ strategy to expand its comprehensive a.....»»

Category: topSource: bizjournalsJan 17th, 2019

Bristol-Myers: EC approves Opdivo plus low dose Yervoy for treatment of RCC

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 14th, 2019